{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T08:38:06Z","timestamp":1777970286454,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc."},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic migraine following eptinezumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PROMISE-2 was a double-blind, placebo-controlled, parallel-group trial that randomized adults with chronic migraine to eptinezumab 100\u2009mg, 300\u2009mg, or placebo IV every 12 weeks for up to 24 weeks (2 infusions). Headache episodes (migraine and non-migraine) and their characteristics were reported in daily electronic diaries during the 28-day baseline and throughout the 24-week treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1072 patients were included in this post hoc analysis. Mean monthly headache days decreased by 8.9 (100\u2009mg) and 9.7 (300\u2009mg) compared to a 7.3 decrease in placebo over the first 4-week interval post initial dose and reductions were maintained throughout the 24-week treatment period. Mean monthly headache episodes also decreased by 8.4 (100\u2009mg) and 9.0 (300 mg) compared to a decrease of 7.1 with placebo. The proportion of headache episodes that were migraine attacks decreased by 11.2% (100\u2009mg), 12.4% (300\u2009mg), and 3.9% (placebo), and among remaining headaches decreases in severe pain, nausea, phonophobia, photophobia, and physical activity limitations were numerically greater than placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with chronic migraine treated with eptinezumab decreased the monthly severity and frequency of headache days and episodes more than placebo. Beyond decreased headache frequency, patients treated with eptinezumab reported a reduction in the percent of remaining headache episodes that were migraine attacks, as well as a decrease in burdensome symptoms of headache episodes, indicating additional decreased headache severity after eptinezumab treatment. Trial registration: ClinicalTrials.gov Identifier: NCT02974153; registered November 23, 2016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024221089567","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T05:30:56Z","timestamp":1648186256000},"page":"1005-1012","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine"],"prefix":"10.1177","volume":"42","author":[{"given":"Peter","family":"McAllister","sequence":"first","affiliation":[{"name":"New England Institute for Neurology and Headache, Stamford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kudrow","sequence":"additional","affiliation":[{"name":"California Medical Clinic for Headache, Santa Monica, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[{"name":"Lundbeck LLC, Deerfield, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Northwest Statistical Consulting, Inc., Woodinville, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H Lundbeck A\/S, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"bibr1-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"bibr2-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0993-0"},{"key":"bibr3-03331024221089567","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition.\n                      Cephalalgia\n                      2018; 38: 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"bibr4-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414552532"},{"key":"bibr5-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1111\/head.13613"},{"key":"bibr6-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1175912"},{"key":"bibr7-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0098-4"},{"key":"bibr8-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000052998.58526.A9"},{"key":"bibr9-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-010-0208-1"},{"key":"bibr10-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01857.x"},{"key":"bibr11-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2008.01867.x"},{"key":"bibr12-03331024221089567","unstructured":"VYEPTI [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc. 2021."},{"key":"bibr13-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"bibr14-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3"},{"key":"bibr15-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"bibr16-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"bibr17-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7665"},{"key":"bibr18-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120"},{"key":"bibr19-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02123-w"},{"key":"bibr20-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1111\/head.14127"},{"key":"bibr21-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01215-9"},{"key":"bibr22-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01190-7"},{"key":"bibr23-03331024221089567","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1767402"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221089567","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024221089567","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024221089567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:31Z","timestamp":1777387771000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/03331024221089567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1177\/03331024221089567"],"URL":"https:\/\/doi.org\/10.1177\/03331024221089567","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]}}}